CJC-1295 (CJC-1295)

Peptide

CJC-1295 · DAC

CJC-1295 is a GHRH analog that amplifies and prolongs the GH pulse triggered by GHRPs. The "no DAC" version (Mod GRF 1-29) should be injected with every GHRP. The DAC version has an 8-day half-life but gives a less physiological GH plateau.

Half-life

30 min (sans DAC) / 8 jours (avec DAC)

Detection

Non détecté usuellement

Injectable

Dosages

Beginner	100 mcg × 2/j
Intermediate	100 mcg × 3/j
Advanced	100–200 mcg × 3/j
Female	100 mcg × 2/day

Frequency : No DAC: with each GHRP · With DAC: 1× / week

Effects

Amplification of the GH pulse
Sustained IGF-1 increase
Recovery ++
Lipolysis
Sense of well-being

Side effects

Mild water retention
Numbness
Facial flush
Mild hypoglycemia post-injection

Support supplements

GHRP-2 or GHRP-6 or Ipamorelin (mandatory for synergistic effect)

Synergies & stacks

GHRP-2GHRP-6IpamorelinMK-677

Avoid

Without a GHRP (CJC alone = limited effect)
With meals (no-DAC version)

Sources

Studies and scientific publications this guide relies on.

Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. doi: 10.1210/jc.2005-1536
RCT chez 21 adultes sains : CJC-1295 (analogue GHRH avec DAC) en injection SC unique augmente la GH plasmatique 2-10× pendant 6 jours et l'IGF-1 1,5-3× pendant 9-11 jours, demi-vie 5,8-8,1 jours, tolérance acceptable aux doses 30 et 60 µg/kg.
Sigalos JT, Pastuszak AW (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. doi: 10.1016/j.sxmr.2017.02.004
Revue clinique : CJC-1295 sous deux formes (avec DAC = demi-vie 8 j ; sans DAC = sermorelin-like, demi-vie 30 min) — le stack moderne combine CJC-1295 sans DAC + ipamorelin pour pulses physiologiques 2-3×/j.
Bowers CY, Momany FA, Reynolds GA, et al. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. doi: 10.1210/endo-114-5-1537
Article fondateur : caractérisation de la voie GHRP distincte de la voie GHRH — base mécanistique des combinaisons modernes (GHRH analog + GHRP) pour amplifier les pulses GH endogènes.
Pope HG Jr, Wood RI, Rogol A, et al. (2014). Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews. doi: 10.1210/er.2013-1058
Énoncé Endocrine Society : CJC-1295 inclus dans le panorama des sécrétagogues GH non médicaux — élévation IGF-1, signal théorique sur la prolifération cellulaire, données long terme limitées.

Related guides

SARMs vs steroids vs peptides

Peptides for bodybuilding

HGH for bodybuilding

GHRP and GHRH peptides

Gear storage and quality

Personalized tracking, dose-response curves and AI advice

Track your cycles with personalized curves based on your weight and profile, tailored AI advice, a daily journal and 59 blood markers.

Free 5-day trial — no credit card

Sources

Studies and scientific publications this guide relies on.

Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. doi: 10.1210/jc.2005-1536

RCT chez 21 adultes sains : CJC-1295 (analogue GHRH avec DAC) en injection SC unique augmente la GH plasmatique 2-10× pendant 6 jours et l'IGF-1 1,5-3× pendant 9-11 jours, demi-vie 5,8-8,1 jours, tolérance acceptable aux doses 30 et 60 µg/kg.

Sigalos JT, Pastuszak AW (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. doi: 10.1016/j.sxmr.2017.02.004

Revue clinique : CJC-1295 sous deux formes (avec DAC = demi-vie 8 j ; sans DAC = sermorelin-like, demi-vie 30 min) — le stack moderne combine CJC-1295 sans DAC + ipamorelin pour pulses physiologiques 2-3×/j.

Bowers CY, Momany FA, Reynolds GA, et al. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. doi: 10.1210/endo-114-5-1537

Article fondateur : caractérisation de la voie GHRP distincte de la voie GHRH — base mécanistique des combinaisons modernes (GHRH analog + GHRP) pour amplifier les pulses GH endogènes.

Pope HG Jr, Wood RI, Rogol A, et al. (2014). Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews. doi: 10.1210/er.2013-1058

Énoncé Endocrine Society : CJC-1295 inclus dans le panorama des sécrétagogues GH non médicaux — élévation IGF-1, signal théorique sur la prolifération cellulaire, données long terme limitées.